This contract involves the delivery of medicinal products. Detailed specifications of the required products are provided in Annex 2 of the procurement documents. The total value of the contract is approximately €22,483,413.96. This opportunity is offered by the Białystok Oncology Center in Poland, a
Contract awarded. Originally published 1 years ago.
No single supplier dominates the field.
In healthcare medical, BIAYSTOK ONCOLOGY CENTER NAMED AFTER MARIE CURIE IN BIAYSTOK has awarded 8 contracts to 8 suppliers.
+2 more suppliers
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This contract opportunity involves the supply of equipment, software, and licenses as part of the digital transformation of the Białystok Oncology Center. The project is divided into several parts: Part 1 includes the delivery, migration, and implementation of the email management system for the cen
This contract involves the supply of medicinal products. Detailed specifications of the required products can be found in Annex 2 of the procurement documents.
This contract involves the design and execution of construction work to adapt the building formerly used by the CZMiS at 23 Ogrodowa Street for the needs of the Białystok Oncology Center (BCO). The project includes the construction of an underground connector for communication with the BCO hospital
This contract involves the supply of medicinal products. Detailed specifications of the required products can be found in Annex 2 of the procurement documents.
Ireland is seeking a qualified occupational health services provider to deliver comprehensive workplace health assessments, medical surveillance, and occupational health advisory services.
NHSBT seeks suppliers of colour-coded EDTA sample tubes with bar-code labels to support testing of 1.5 million annual blood and tissue donations across two English facilities.
BHRUT seeks an outsourced dermatology service provider to treat 800 waiting list patients from November 2026 to March 2027 (£520,000 contract value).
A competitive NHS framework agreement enabling the supply of unlicensed imported medicines to healthcare organisations and eligible public bodies, subject to strict regulatory compliance and quality assurance standards.
